-
公开(公告)号：US20030186976A1
公开(公告)日：2003-10-02
申请号：US10435746
申请日：2003-05-12
Inventor： Yoshimitsu Naniwa , Hiroshi Imai , Tomohide Ida , Emiko Muratani , Kazuo Kitai , Yoshinori Sugimoto , Tomomi Kosugi , Akiko Takeuchi , Kunihito Watanabe , Takami Tomiyama , Tomio Takeuchi , Masa Hamada
IPC: A61K031/5377 , A61K031/4433 , A61K031/366 , A61K031/4025 , C07D413/14 , C07D45/14
CPC classification number: C07D405/14 , C07D407/04 , C07D407/14 , C07D409/14 , C07D413/14 , C07D417/04
Abstract: There is provided benzofuryl-null-pyrone derivative represented by the following structural formula (I): 1 wherein R1 represents a hydrogen atom or an alkyl group of 1 to 5 carbons; R2 represents hydrogen, nullCOnullR5 or nullSO2R6; R3 represents hydrogen, an alkyl group of 1 to 5 carbons, etc.; and R4 is a substituent attached to the 4-carbon, 5-carbon, 6-carbon or 7 carbon of the benzofuran ring; and their salts. The compounds are useful as therapeutic agent for hypertriglyceridemia, lipid metabolism enhancers, or prophylactic and/or therapeutic agents for arteriosclerosis.
Abstract translation: 提供由以下结构式（I）表示的苯并呋喃基-α-吡喃酮衍生物：其中R 1表示氢原子或1至5个碳的烷基; R 2表示氢，-CO-R 5或-SO 2 R 6; R 3表示氢，碳原子数为1〜5的烷基等。 并且R 4是连接到苯并呋喃环的4-碳，5-碳，6-碳或7碳的取代基; 和它们的盐。 该化合物可用作高甘油三酯血症的治疗剂，脂质代谢增强剂，或用于动脉硬化的预防和/或治疗剂。
-
公开(公告)号：US20210270844A1
公开(公告)日：2021-09-02
申请号：US16304219
申请日：2017-05-23
Inventor： Kayoko SAITO , Reiko ARAKAWA , Masayuki ARAKAWA
IPC: G01N33/68 , G01N33/569 , G01N21/64
Abstract: A method is provided which makes it possible to analyze an SMN protein nuclear body that serves as a more highly reliable biomarker. The present method is for analyzing the expression of an SMN protein nuclear body, comprising: labeling one or more surface antigen markers of blood-derived nucleated cells in a sample containing the nucleated cells with one or more label antibodies; labeling SMN protein in the nucleated cells; labeling nuclei of the nucleated cells; selecting one cell population from a plurality of cell populations in which nuclei and SMN protein in the nucleated cells have been labeled and which have been classified based on, e.g., surface antigen markers labeled with label antibodies; and analyzing the expression of an SMN protein nuclear body of the selected cell population based on a label on SMN protein. The method comprises performing imaging flow cytometry using an objective lens with a predetermined magnification.
-
公开(公告)号：US20180214470A1
公开(公告)日：2018-08-02
申请号：US15747581
申请日：2016-07-29
Inventor： Yoshiaki TAKAHASHI , Eijiro UMEMURA , Takashi IDA , Masayuki IGARASHI
IPC: A61K31/7036 , A61P31/04
Abstract: A compound represented by the following general formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition thereof, and the use thereof to prevent or treat infectious diseases and a method to prevent or treat infectious diseases using those regimen are disclosed. The compound represented by formula (I) has an antibacterial activity against both gram-positive and gram-negative bacteria, and is useful in the prevention or treatment of infectious diseases caused by these bacteria.
-
公开(公告)号：US20170115297A1
公开(公告)日：2017-04-27
申请号：US15300456
申请日：2015-04-03
Inventor： Kayoko SAITO , Reiko ARAKAWA , Masayuki ARAKAWA , Akio NOMOTO (Deceased)
CPC classification number: G01N33/582 , C07K14/435 , G01N21/6428 , G01N33/48 , G01N33/56972 , G01N33/6875 , G01N33/6896 , G01N2021/6439 , G01N2333/47 , G01N2800/2878
Abstract: Provided is a method for detecting the expression of SMN protein, said method comprises: a step for labeling SMN protein in a sample, said sample containing nucleated cells derived from blood; a step for labeling the nuclei of the nucleated cells in the sample; a step for selecting a cell population of the nucleated cells in which nuclei and SMN protein are labeled; and a step for detecting the expression of the SMN protein on the basis of the label for the SMN protein in the selected cell population.
-
25.发明授权Compound; tautomer and geometric isomer thereof; salt of said compound, tautomer, or geometric isomer; method for manufacturing said compound, tautomer, isomer, or salt; antimicrobial agent; and anti-infective drug 有权复合; 互变异构体及其几何异构体; 所述化合物的盐，互变异构体或几何异构体; 制备所述化合物，互变异构体，异构体或盐的方法; 抗菌剂; 和抗感染药公开(公告)号：US09512075B2
公开(公告)日：2016-12-06
申请号：US14436316
申请日：2013-10-17
Inventor： Teruhiko Ishikawa , Tatsuya Kitaoka , Shyota Katayama , Yoshikuni Itoh , Ryutaro Utsumi , Masayuki Igarashi
IPC: C07D209/34 , C07D311/56
CPC classification number: C07D209/34 , C07D311/56
Abstract: The present invention provides compounds belonging to 3-acyloxyindole compounds or 3-acyl-4-hydroxycoumarin compounds, a tautomer or geometric isomer thereof, or a salt thereof and methods for producing the same, which compounds are useful as antibacterial agent and as therapeutic drugs against infectious diseases.
Abstract translation: 本发明提供了属于3-酰氧基吲哚化合物或3-酰基-4-羟基香豆素化合物，其互变异构体或几何异构体或其盐的化合物及其制备方法，该化合物可用作抗菌剂和作为治疗药物 针对传染病。
-
Patent Agency Ranking
公开(公告)号：US09260465B2
公开(公告)日：2016-02-16
申请号：US13970841
申请日：2013-08-20
Inventor： Yoshihiko Kobayashi , Yoshihisa Akiyama , Takeshi Murakami , Nobuto Minowa , Masaki Tsushima , Yukiko Hiraiwa , Shoichi Murakami , Mitsuhiro Abe , Kazushige Sasaki , Shigeru Hoshiko , Toshiaki Miyake , Yoshiaki Takahashi , Daishiro Ikeda
IPC: C07H15/234 , C07H1/00 , C07H15/224
CPC classification number: C07H15/234 , C07H15/224
Abstract: This invention relates to novel aminoglycoside antibiotics, which have potent antimicrobial activity against bacteria, which induce infectious diseases, particularly MRSA, and has no significant nephrotoxicity, and process for producing them. More particularly, the present invention relates to compounds represented by formula (Ia) or their pharmacologically acceptable salts or solvates, or their diastereomer mixtures, antimicrobial agents comprising them, and a process for producing them.
-
公开(公告)号：US09187498B2
公开(公告)日：2015-11-17
申请号：US14658297
申请日：2015-03-16
Applicant: Microbial Chemistry Research Foundation
Inventor： Masakatsu Shibasaki , Naoya Kumagai
IPC: C07D405/12 , C07D307/33 , C07D215/227 , C07F7/08 , B01J31/24 , C07D309/30 , C07B53/00 , C07C323/12 , C07C381/12 , C07D301/02 , C07D303/22 , C07C323/16 , C07F7/12 , C07F9/50 , C07F9/6561 , C07F7/18
CPC classification number: C07F7/0812 , B01J31/24 , C07B53/00 , C07C323/12 , C07C323/16 , C07C381/12 , C07D215/227 , C07D301/02 , C07D303/22 , C07D307/33 , C07D309/30 , C07D405/12 , C07F7/12 , C07F7/1804 , C07F9/5059 , C07F9/65616 , Y02P20/55
Abstract: A compound represented by the following General Formula (1): where R1 represents a protective group for a hydroxyl group or a hydrogen atom, and R2 represents a methyl group or an ethyl group.
-
公开(公告)号：US20150140018A1
公开(公告)日：2015-05-21
申请号：US14400207
申请日：2013-05-13
Inventor： Manabu Kawada , Hiroyuki Inoue , Shuichi Sakamoto , Masunori Kajikawa , Masahito Sugiura , Sakiko Urano
IPC: C07K16/30 , G01N33/574
CPC classification number: C07K16/30 , A61K39/00 , A61K2039/505 , C07K16/2803 , C07K16/3069 , C07K2317/34 , C07K2317/732 , C07K2317/734 , C07K2317/76 , G01N33/57484 , G01N33/57492 , G01N2333/705
Abstract: An object is to find a target molecule effective for cancer treatments and the like and to provide an antibody capable of specifically binding to the molecule, an anticancer agent comprising the antibody as an active ingredient, and so forth. Hence, prostate cancer cell lines (LNCaP-CR cells and LNCaP cells) were compared by SST-REX, and CXADR was identified as a molecule involved in tumor formation and so on. Then, a monoclonal antibody against CXADR was prepared, and the anti-cancer activity, ADCC activity, CDC activity, and so forth were examined. The result revealed that an antibody capable of binding to an epitope present at positions 181 to 230 of a CXADR protein derived from human exhibited an anti-cancer activity against prostate cancer cells, pancreatic cancer cells, and colorectal cancer cells. Further, it was also revealed that the antibody had an ADCC activity and a CDC activity. Moreover, the structures of light chain and heavy chain variable regions of the antibody were successfully determined.
Abstract translation: 目的是找到对癌症治疗等有效的靶分子，并提供能够特异性结合分子的抗体，包含抗体作为活性成分的抗癌剂等。 因此，通过SST-REX比较前列腺癌细胞系（LNCaP-CR细胞和LNCaP细胞），将CXADR鉴定为涉及肿瘤形成的分子等。 然后，制备针对CXADR的单克隆抗体，检测抗癌活性，ADCC活性，CDC活性等。 结果表明，能够结合存在于衍生自人的CXADR蛋白的第181至230位的表位的抗体对前列腺癌细胞，胰腺癌细胞和结肠直肠癌细胞具有抗癌活性。 此外，还显示抗体具有ADCC活性和CDC活性。 此外，成功测定了抗体轻链和重链可变区的结构。
-
公开(公告)号：US08981123B2
公开(公告)日：2015-03-17
申请号：US14301562
申请日：2014-06-11
Applicant: Microbial Chemistry Research Foundation
Inventor： Masakatsu Shibasaki , Naoya Kumagai
IPC: B01J31/24 , C07D309/30 , C07B53/00 , C07C323/12 , C07C381/12 , C07F9/6561 , C07D301/02 , C07D303/22 , C07D307/33 , C07C323/16 , C07F7/12 , C07F9/50
CPC classification number: C07F7/0812 , B01J31/24 , C07B53/00 , C07C323/12 , C07C323/16 , C07C381/12 , C07D215/227 , C07D301/02 , C07D303/22 , C07D307/33 , C07D309/30 , C07D405/12 , C07F7/12 , C07F7/1804 , C07F9/5059 , C07F9/65616 , Y02P20/55
Abstract: A compound represented by the following General Formula (1): where R1 represents a protective group for a hydroxyl group or a hydrogen atom, and R2 represents a methyl group or an ethyl group.
Abstract translation: 由以下通式（1）表示的化合物：其中R1表示羟基或氢原子的保护基，R2表示甲基或乙基。
-
30.发明申请Readthrough Inducing Agent and Drug for Treating Genetic Disease Caused by Nonsense Mutation 有权阅读诱导剂和药物治疗由无义突变引起的遗传病公开(公告)号：US20150005249A1
公开(公告)日：2015-01-01
申请号：US14486321
申请日：2014-09-15
Inventor： Ryoichi Matsuda , Masataka Shiozuka , Akira Wagatsuma , Yoshikazu Takahashi , Daishiro Ikeda , Yoshiaki Nonomura , Masafumi Matsuo , Atsushi Nishida
IPC: A61K31/7036
CPC classification number: A61K31/7036 , A61K48/00 , C07H15/234
Abstract: A readthrough inducing agent for inducing readthrough of a premature stop codon generated by nonsense mutations, the readthrough inducing agent comprising a compound having a structure expressed by the following Structural Formula (A), and a drug for treating a genetic disease caused by nonsense mutations, the drug comprising the readthrough inducing agent.
Abstract translation: 一种用于诱导通过无义突变产生的过早终止密码子的穿透的通过诱导剂，所述穿透诱导剂包含具有由以下结构式（A）表示的结构的化合物和用于治疗由无义突变引起的遗传疾病的药物， 所述药物包含通过诱导剂。
-
-
-
-
-
-
-
-
-
Search Results
60
records
(took 0.029 seconds)
